SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Preferred Stock Dividends, Income Statement Impact
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Preferred Stock Dividends, Income Statement Impact of $402.06 thousand for the 12-month period ending 2022-12-31, per its 10-K/A filed 2024-09-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2024-09-04
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. preferred stock dividends, income statement impact for the quarter ending 2022-12-31 was $331.06K, a 1185.25% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. preferred stock dividends, income statement impact for the quarter ending 2022-09-30 was $19.47K, a 24.43% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. preferred stock dividends, income statement impact for the quarter ending 2022-06-30 was $25.77K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. preferred stock dividends, income statement impact for the quarter ending 2022-03-31 was $25.77K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. preferred stock dividends, income statement impact for fiscal 2022 was $402.06K, a 290.12% increase from fiscal 2021.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. preferred stock dividends, income statement impact for fiscal 2021 was $103.06K.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month | Preferred Stock Dividends, Income Statement Impact 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $331.06K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $350.53K derived: sum of 2 quarters · filed 2024-09-04 | $376.30K derived: sum of 3 quarters · filed 2024-09-04 | $402.06K 10-K/A · filed 2024-09-04 | $71.01K 10-K · filed 2023-03-15 |
| 2022-09-30 | $19.47K 10-Q · filed 2023-11-13 | $45.24K derived: sum of 2 quarters · filed 2023-11-13 | $71.01K 10-Q · filed 2023-11-13 | $96.77K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $25.77K 10-Q · filed 2023-08-14 | $51.54K 10-Q · filed 2023-08-14 | $77.29K derived: sum of 3 quarters · filed 2023-08-14 | $103.06K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $25.77K 10-Q · filed 2023-05-25 | $51.53K derived: sum of 2 quarters · filed 2023-05-25 | $77.29K derived: sum of 3 quarters · filed 2023-05-25 | ||
| 2021-12-31 | $25.76K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $51.53K derived: sum of 2 quarters · filed 2023-03-15 | $103.06K 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $25.77K 10-Q · filed 2022-11-14 | $77.30K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |